# Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

Source: https://onco.cc/trials/nct07561060/  
OnCo record `nct07561060` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of tislelizumab, capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, now recruiting.

## Summary

Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy is a phase 1/2, interventional study registered as NCT07561060 by Fudan University, with a registry enrolment figure of 50 participants, started 2024-01-01 and due to reach its primary completion in 2027-12. Interventions recorded: Tislelizumab; Capecitabine; Oxaliplatin; Capecitabine. Conditions listed: Rectal Cancer. Primary outcome: Complete Response rate (CR rate). Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TNTIT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07561060
- Phase: 1/2
- Setting: A Single-arm, Multicenter, Phase II Clinical Study of Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy in Resectable Low Rectal Cancer
- Sponsor: Fudan University
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07561060: https://clinicaltrials.gov/study/NCT07561060

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07561060.json